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Abstract
 
Helicobacter pylori
 
 infection induces the appearance of inflammatory infiltrates, consisting mainly
of neutrophils and monocytes, in the human gastric mucosa. A bacterial protein with neutro-
phil activating activity (HP-NAP) has been previously identified, but its role in infection and
immune response is still largely unknown. Here, we show that vaccination of mice with HP-
NAP induces protection against
 
 H
 
.
 
 pylori
 
 challenge, and that the majority of infected patients
produce antibodies specific for HP-NAP, suggesting an important role of this factor in immu-
nity. We also show that HP-NAP is chemotactic for human leukocytes and that it activates
their NADPH oxidase to produce reactive oxygen intermediates, as demonstrated by the trans-
location of its cytosolic subunits to the plasma membrane, and by the lack of activity on
chronic granulomatous disease leukocytes. This stimulating effect is strongly potentiated by tu-
 
mor necrosis factor 
 
a
 
 and interferon 
 
g
 
 and is mediated by a rapid increase of the cytosolic cal-
cium concentration. The activation of leukocytes induced by HP-NAP is completely inhibited
by pertussis toxin, wortmannin, and PP1. On the basis of these results, we conclude that HP-
NAP is a virulence factor important for the 
 
H
 
.
 
 pylori
 
 pathogenic effects at the site of infection
and a candidate antigen for vaccine development.
Key words: neutrophils • monocytes • NADPH oxidase • chemotaxis • 
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Introduction
 
Infection of the stomach mucosa by 
 
Helicobacter pylori
 
 is ac-
companied by a large infiltration of the mucosa by neutro-
phils, which are believed to contribute substantially to 
 
H
 
.
 
pylori
 
–induced gastritis (1–5). Indeed, there is a good corre-
lation between the degree of mucosal damage and neutro-
phil infiltration (1, 6, 7). Several studies have provided evi-
dence for the presence of protein component(s) in 
 
H
 
.
 
 pylori
 
water extracts that attract and activate neutrophils and
other inflammatory cells (8–17). Moreover, 
 
H
 
.
 
 pylori
 
 strains
capable of neutrophil activation were found more fre-
quently in patients affected by peptic ulcer disease than ac-
tive chronic gastritis only (18).
 
An 
 
H
 
.
 
 pylori
 
 protein capable of promoting neutrophil
adhesion to endothelial cells was purified and found to be
a 150-kD decamer composed of identical subunits (19,
20). It was termed 
 
H
 
.
 
 pylori
 
 neutrophil-activating protein
 
(HP-NAP)
 
1
 
 because it induced neutrophils to adhere to
endothelial cells and to reduce nitroblue tetrazolium
(NBT), via the production of reactive oxygen intermedi-
ates (ROI) (20). A considerable variation in the level of
neutrophil adhesion promoting activity among different
 
H
 
.
 
 pylori
 
 strains was documented (20), suggesting a variable
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Abbreviations used in this paper:
 
 [Ca
 
2
 
1
 
]
 
i
 
, intracellular Ca
 
2
 
1
 
 concentration;
CGD, chronic granulomatous disease; DPI, diphenyleneiodonium
chloride; HP-NAP, 
 
Helicobacter pylori
 
 neutrophil-activating protein;
HRP, horseradish peroxidase; NBT, nitroblue tetrazolium; PI3-K,
phosphatidylinositol 3-kinase; PLC, phospholipase C; ROI, reactive
oxygen intermediates. 
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level of expression of the protein, similar to what was
found for VacA (21). HP-NAP is localized in the bacterial
cytosol and is released upon autolysis. HP-NAP can bind
to the external surface of the outer membrane (22), in a
similar manner as urease (23). In such a location, HP-NAP
can mediate the binding of 
 
H
 
.
 
 pylori
 
 to the cell surface via
interaction with carbohydrates (24). Thus, notwithstand-
ing the possible role of HP-NAP in 
 
H
 
.
 
 pylori
 
–associated
diseases and in the human immune response to the bacte-
rium, very little is known about these aspects of HP-NAP
activity.
Very recently, computer-assisted molecular modelling,
and spectroscopic and electron microscopic analysis indi-
cated that HP-NAP is a 4-helix bundle protein forming
dodecamers capable of binding a maximum of 500 atoms of
iron per oligomer (25). Database searches indicate that HP-
NAP–like molecules are present in a variety of pathogenic
bacteria, but no data on their biological activities are re-
ported. Thus, HP-NAP appears to be the prototype for a
highly conserved class of bacterial homooligomeric pro-
teins, and further studies are needed to characterize their
activity particularly with respect to the immune and in-
flammatory responses.
Here, we show that HP-NAP is important both for im-
munity and for pathogenesis. Indeed, we found that the
majority of the infected patients have antibodies against this
antigen, and that vaccination of mice with HP-NAP in-
duces protection against a subsequent challenge with 
 
H. py-
lori
 
. Furthermore, we show that HP-NAP is chemotactic
for neutrophils and monocytes and that it induces ROI
production in humans by activating the plasma membrane
NADPH oxidase via a signaling pathway involving trimeric
G protein, phosphatidylinositol 3-kinase (PI3-K), Src family
tyrosine kinases, and rise in cytosolic calcium. TNF-
 
a
 
 and
IFN-
 
g
 
 prime neutrophils in such a way as to potentiate the
effect of HP-NAP. These results identify HP-NAP as a vir-
ulence factor relevant for the pathogenic effects of 
 
H
 
.
 
 pylori
 
at the sites of infection, and point to HP-NAP as a possible
candidate for a multicomponent vaccine against 
 
H
 
.
 
 pylori
 
.
 
Materials and Methods
 
Reagents.
 
HP-NAP was cloned and expressed in 
 
Bacillus subtilis
 
to avoid contamination with LPS. Two preparations of HP-NAP
were isolated from 
 
H. pylori
 
 CCUG strain as described previously
(20). CagA and 
 
H
 
.
 
 pylori
 
 extracts were prepared as described pre-
viously (16, 26, 27). The purification and the characteristics of the
LTK63 mutant of 
 
Escherichia coli
 
 heat-labile enterotoxin have also
been reported (28). TNF-
 
a
 
 and IFN-
 
g
 
 were obtained from Soci-
età Italiana Chimici; FMLP, wortmannin, homovanillic acid,
horseradish peroxidase (HRP), and Fura-2 were purchased from
Sigma Chemical Co.; diphenyleneiodonium chloride (DPI) and
PP1 were from Calbiochem; pertussis toxin was prepared as de-
scribed (29). Anti-p47
 
phox
 
, anti-p67
 
phox
 
, and anti-p40
 
phox
 
 affinity-
purified rabbit polyclonal antibodies were a gift of Dr. F. Wientjes
(Department of Medicine, University College, London, UK). So-
lutions used throughout the experiments were prepared with en-
dotoxin-free water for clinical use.
 
Assay of HP-NAP–specific Antibodies and Mice Immunization.
 
Serum samples from 35 healthy adults, known to be positive for
 
H
 
.
 
 pylori
 
, were tested for the presence of anti–HP-NAP, anti-
CagA, and anti–
 
H
 
.
 
 pylori
 
 IgG antibodies using an ELISA origi-
nally reported by Xiang et al. (30) with minor modifications.
Some of these serum samples were also tested by immunoblotting,
using an 
 
H
 
.
 
 pylori
 
 sonicate, as described (30).
CD-1–specific pathogen-free mice were immunized orally and
then challenged with 
 
H
 
.
 
 pylori
 
 according to described procedures
(16, 26). In brief, groups of 10 mice (Charles River) were im-
munized intragastrically at days 0, 7, and 14 with saline alone
(control) or with saline containing 100 mg of 
 
H
 
.
 
 pylori
 
 CagA,
glutathione 
 
S
 
-transferase (GST)–HP-NAP, or 
 
H
 
.
 
 pylori
 
 lysate to-
gether with 10 mg of LTK63 mutant as a mucosal adjuvant. At
days 21, 23, and 25, all mice were challenged intragastrically with
10
 
9
 
 CFU of 
 
H
 
.
 
 pylori
 
 strain SPM326, a clinical isolate that has
been adapted to colonize the mouse, as described previously in
detail (16). At day 35, mice were killed, the stomachs were re-
moved, and colonization was determined by culture as reported
(26). Mice were considered as protected (not infected) when no
 
H
 
.
 
 pylori
 
 colony was detected on the stomach culture plates.
 
Cells.
 
Neutrophils and monocytes (95–98% purity) were iso-
lated from buffy coats of healthy donors or patients with chronic
granulomatous (CGD), as reported previously (31, 32).
 
Assays of Chemotaxis and 
 
b
 
2 Integrin Expression.
 
Neutrophil
migration was assessed using 3-
 
m
 
m-pore transwells (growth area 1
cm
 
2
 
; Costar). Neutrophils were suspended in PBS containing 1
mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, and 10% FCS, pH 7.2, at 2 
 
3 
 
10
 
6
 
/ml,
and 300 
 
m
 
l of the cell suspensions was added to the top well while
1.2 ml medium containing the agonist was added to the bottom
well. After fixation with 1.5% glutaraldehyde, migrated cells were
counted by FACS
 
®
 
 using polystyrene beads (Polysciences) as an
internal standard (33).
Expression of 
 
b
 
2 integrins was evaluated by FACS
 
®
 
 analysis
with the mouse anti–human CD18 mAb IB4. In brief, neutro-
phils and monocytes were incubated at 37
 
8
 
C for 30 min in the
presence of HP-NAP or FMLP, centrifuged, and then stained
with an FITC-conjugated rabbit anti–mouse polyclonal antibody.
After extensive washing, cells were analyzed with a Becton Dick-
inson FACS
 
®
 
 apparatus.
 
Stimulation of ROI Production.
 
The production of ROI was
measured in stirred cell suspension (10
 
6
 
/ml) in HBSS at 37
 
8
 
C as
H
 
2
 
O
 
2
 
-HRP–dependent oxidation of homovanillic acid by using a
spectrofluorimeter (model LS 50B; PE Biosystems) as described
previously (34).
 
Measurement of Cytosolic Ca
 
2
 
1
 
.
 
Ca
 
2
 
1
 
 was monitored in neu-
trophils loaded with 2 
 
m
 
M Fura-2 (32, 34, 35) for 25 min at
378C. After loading, cells were diluted fivefold with HBSS, and
incubation was prolonged for 25 min at 378C. The cell suspension
was centrifuged at 1,000 rpm for 5 min, and the pellet was resus-
pended in HBSS at a final concentration of 2 3 107 PMNs/ml.
106 cells/ml were treated with HP-NAP or FMLP (1 mM final
concentration), and changes in cytosolic calcium concentration
were measured by fluorescence spectroscopy in an LS 50B appa-
ratus (excitation wavelength 335–380 nm, and emission 509 nm;
PE Biosystems). Discrimination between calcium release from in-
tracellular stores and extracellular influx was achieved by addition
of 2 mM EGTA for 60 s at 378C before agonist treatment.
Inhibitory Effect of Pertussis Toxin, Wortmannin, DPI, PP1, TNF-a,
and IFN-g. To evaluate the effect on the respiratory burst,
106 cells/ml were treated with 800 ng/ml of pertussis toxin for
120 min at 378C; wortmannin for 5 min, or DPI (10 mM) or PP11469 Satin et al.
for 5 min at 378C; or with 5 ng/ml of TNF-a for 15 min, or
IFN-g for 30 min at 378C. After incubation, the cells were stim-
ulated with HP-NAP or FMLP and the production of H2O2 was
measured.
To evaluate the effect on intracellular Ca21 concentration
([Ca21]i), 106 neutrophils/ml loaded with Fura-2 were incubated
for 120 min with 800 ng/ml of pertussis toxin, or for 5 min with
PP1 or wortmannin at 378C. After incubation, cells were treated
with HP-NAP or FMLP and the calcium level was monitored as
described above.
NADPH Oxidase Activation. The activation of NADPH oxi-
dase was investigated by evaluating the translocation of cytosolic
components p47phox, p67phox, and p40phox from the cytosol to the
plasma membrane after cell stimulation, as described previously
(36). In brief, neutrophils (7 3 106 cells/ml) were incubated at
378C under stirring with or without the agonists. At the indicated
time, cells were disrupted by sonication (two 15-s cycles at 200 W,
48C). The postnuclear supernatants were loaded onto a dis-
continuous gradient of 1.5 ml of 15% (wt/wt) sucrose layered on
1.5 ml of 34% (wt/wt) sucrose in relaxation buffer (37, 38) and
centrifuged at 150,000 g (45 min, 48C). The light membranes
were collected at the 15%/34% sucrose interface, washed with re-
laxation buffer, centrifuged at 150,000 g (30 min, 48C), resus-
pended in 150 ml of sample buffer, and boiled for 5 min. Aliquots
of samples containing the same amounts of proteins were sub-
jected to SDS-PAGE on 12% polyacrylamide gels and incubated
overnight with 1:500 diluted anti-p47phox, anti-p67phox, and anti-
p40phox antibodies. All of the subsequent steps for enhanced
chemiluminescence Western blotting were performed as detailed
elsewhere (36). In separate samples, kept under the same condi-
tions of incubation, the stimulation of H2O2 production was
measured to control the effect of the agonists.
Results
HP-NAP Is an Important Antigen in the Human Immune
Response. In a first set of experiments, we tested by
ELISA if serum samples from individuals infected with H.
pylori contained antibodies directed against HP-NAP, and
found that 21 (60%) out of 35 subjects positive for H. pylori
produced antibodies specific for HP-NAP. Antibodies spe-
cific for CagA, an immunodominant antigen of H. pylori
(26, 30, 37, 38), were detected in 26 (74%) of the subjects.
These data indicate that HP-NAP induces specific immune
responses in humans after infection with H. pylori, with a
prevalence close to that of CagA. Fig. 1 A shows the result
of a representative immunoblot experiment using HP-
NAP1 and HP-NAP2 serum samples. HP-NAP is a 17-kD
protein (20, 22) that runs at the gel front of low cross-
linked polyacrylamide gels, which may explain why this
strong anti–HP-NAP immunoreactivity has gone unno-
ticed in previous routine analyses of antigen specificities of
the antibodies present in antisera of H. pylori–infected pa-
tients. A more extensive analysis of HP-NAP immunoreac-
tivity is underway (our unpublished results); however, the
present data clearly indicate that HP-NAP is an important
antigen in the human immune response against H. pylori.
HP-NAP Induces an H. pylori Immunoprotective Response in
Mice. To test whether the HP-NAP antigen plays a role
in immunoprotection, groups of mice were immunized
orally with HP-NAP. Saline and CagA and an H. pylori
sonicate were used as negative and positive controls, re-
spectively. After challenge with the H. pylori strain
SPM326, protection was obtained in 80% of the mice im-
munized with recombinant HP-NAP (Fig. 1 B). The level
of protection induced is comparable to that obtained with
known protective antigens such as CagA and the H. pylori
total extract. These results show that HP-NAP is a protein
that confers protection in this animal model of H. pylori in-
Figure 1. HP-NAP is immunogenic in humans and protec-
tive in mice. (A) The sera of an H. pylori–infected patient (1)
and a negative control (2) were assayed by immunoblotting
followed by development with enhanced chemiluminescence
on samples of H. pylori total sonicates (left lanes) and purified
recombinant HP-NAP (right lanes), subjected to SDS-PAGE,
and then transferred onto nitrocellulose paper. Numbers on
the left refers to the position of molecular weight markers (in
kD). The last lane (aNAP) shows an immunoblot of recombi-
nant HP-NAP stained with an anti–HP-NAP antiserum ob-
tained from rabbits. (B) Groups of 10 CD-1 mice were immu-
nized three times intragastrically with the indicated antigens
together with the LTK63 mutant as a mucosal adjuvant, and
then challenged with 109 CFU of H. pylori strain SPM326 (see
Materials and Methods for details). Mice were considered pro-
tected when no colonies were counted from their stomachs.
Figure 2. Dose–response stimulation of HP-NAP chemotaxis in neu-
trophils and monocytes. The chemotactic activity of HP-NAP on human
neutrophils and monocytes is compared with that of FMLP. Chemotaxis
was measured in Costar transwells as specified in the Materials and Meth-
ods. Bars represent the average of three independent experiments per-
formed in duplicates, and the SD values are given at the top.1470 H. Pylori Neutrophil-activating Protein Is Chemotactic and Immunogenic
fection, as already demonstrated with other bacterial anti-
gens such as CagA, native and recombinant VacA, and ure-
ase (27, 39, 40).
These in vivo findings in both humans and mice, to-
gether with the notion of the existence of genes encoding
for HP-NAP–like proteins in many pathogenic bacteria,
prompted us to further define the biological activity of HP-
NAP at the molecular and cellular levels.
HP-NAP Stimulates Chemotaxis and Integrin Expression in
Monocytes and Neutrophils. The strong infiltration of neu-
trophils typical of H. pylori–associated gastritis (1–5) raises
the possibility that bacterial virulence factors display
chemotactic activity. Fig. 2 shows that indeed HP-NAP
induces a dose-dependent stimulation of chemotactic mi-
gration of neutrophils and monocytes.
Previous reports have shown that chemoattractants such
as formyl peptides, C5a, and IL-8 upregulate b2 integrin
expression on polymorphonuclear leukocytes and mono-
cytes (41–43). As this process is involved in leukocyte ex-
travasation (41–43), the ability of HP-NAP to trigger in-
creased expression of b2 integrin was tested with an mAb
recognizing the heterodimer common b chain (CD18).
This allows evaluation of LFA-1, CR3, and p150/95 ex-
pression. Fig. 3 shows that HP-NAP induces in neutrophils
and monocytes a consistent increase of b2 integrin expres-
sion, very similar to that induced by FMLP.
HP-NAP Stimulates the Production of ROI. These bio-
logical properties of HP-NAP called for a detailed analysis
of their mode of activation of human leukocytes. It was
previously reported that HP-NAP induces neutrophils to
reduce NBT via increased production of ROI (20). Here,
we have assayed quantitatively the time course of the stim-
ulant activity of HP-NAP on both human neutrophils and
monocytes (Fig. 4). The stimulation of ROI production is
detectable within a few minutes after the addition of HP-
NAP and remains linear for 30–40 min. HP-NAP acts in a
dose-dependent manner and, at any dose, the stimulation
of ROI production is slower than that induced by FMLP.
However, the magnitude of effect attained at the maximal
doses of the two stimulants is similar (Fig. 4). As with
FMLP (44), the stimulation of ROI production by HP-
NAP is potentiated about four times by cytochalasin B (5
mg/ml added 5 min before the stimulant; not shown).
HP-NAP is a dodecamer, and strongly denaturing con-
ditions are necessary to dissociate it into monomers (25).
Presumably, the neutrophil and monocyte activating form
of HP-NAP is the dodecameric species, though we cannot
exclude the possibility that a dissociation takes place at the
Figure 3. HP-NAP upregulates the expression of b2 inte-
grins in neutrophils and monocytes. The HP-NAP–induced
expression of the protein on the cell surface was determined
by FACS® analysis with a specific mAb: (A) control cells; (B)
cells treated with 0.2 mM FMLP for 30 min at 378C; (C) cells
treated with 0.5 mM HP-NAP for 30 min at 378C.
Figure 4. Stimulation of H2O2 production by differ-
ent doses of HP-NAP in human peripheral blood neu-
trophils (A) and monocytes (B). H2O2 was measured
with the homovanillic acid method (reference 34).
Very similar results were obtained by assaying the re-
duction of cytochrome c (not shown). Points are the
average of five different experiments run in triplicate,
and bars represent SD values. Symbols indicate: j,
control; r, the data obtained with HP-NAP purified
from H. pylori (average value of data obtained from two
different preparations); all other points shown here and
in the following pictures were obtained with highly
purified recombinant HP-NAP expressed in B. subtilis:
m, 0.6 mM HP-NAP; ., 1.2 mM HP-NAP; d, 3 mM
HP-NAP; s, 1 mM FMLP.1471 Satin et al.
neutrophil cell surface. Considering dodecameric HP-NAP
as the active species, its effectiveness in stimulating neutro-
phils in molar terms is comparable to that of FMLP.
IFN-g and TNF-a Strongly Potentiate the Effect of HP-
NAP. Several mediators of the inflammatory response,
including the proinflammatory cytokines TNF-a and IFN-g,
potentiate the stimulus-induced activation of the NADPH
oxidase of macrophages (36, 45–48). Fig. 5 shows that
TNF-a and IFN-g effectively prime human neutrophils
with respect to the production of ROI induced by HP-
NAP. Similar results were obtained with monocytes (not
shown). This finding is particularly relevant in the context
of the chronic infection established by H. pylori, where a
synergistic effect among HP-NAP and the cytokines may
amplify the pathogenic effect of the ROI.
HP-NAP–induced ROI Production Is Mediated by NADPH
Oxidase. Several cellular sources may be involved in the
production of ROI stimulated by exposure of neutrophils
to HP-NAP, including the mitochondrial respiratory
chain, microsomal enzymes, xanthine oxidase, the arachi-
donic acid cascade, unidentified NADH–NADPH-depen-
dent enzymes, and the classical plasma membrane NADPH
oxidase (49, 50). The inactive form of the oxidase is present
in resting phagocytes and consists of membrane-bound
components (gp91phox and p22phox), the flavocytochrome
b558, and cytosolic components (p47phox, p67phox, p40phox,
and Rac1/Rac2). The oxidase is activated by multiple sig-
nal transduction pathways, all of them causing the translo-
cation of the cytosolic subunits to the plasma membrane,
where they associate to cytochrome b558 and activate the
univalent reduction of oxygen to superoxide anion by the
cytosolic NADPH (51). To determine if the NADPH
oxidase is the source of the ROI production induced by
HP-NAP, we assayed for the translocation of its cytosolic
components to the plasma membrane by subcellular frac-
tionation of neutrophils and monocytes treated or not treated
with HP-NAP. Fig. 6 shows that antibodies specific for
p47phox, p67phox, and p40phox detect minor amounts of these
proteins in the plasma membrane fraction of unstimulated
neutrophils, whereas they strongly stain the same fraction
obtained from cells stimulated with HP-NAP or with the
classical agonist PMA. These results imply that HP-NAP
induces the translocation of the cytosolic subunits of the
NADPH oxidase from the cytosol to the membrane,
thereby causing its activation to produce ROI.
To further prove the central role of NADPH oxidase in
the HP-NAP effect, we used neutrophils and monocytes
from one CGD patient. CGD is an inherited condition
where the absence of cytochrome b (X-linked form) or of
p47phox or p67phox (autosomal form) results in an inactive
NADPH oxidase (52). Thus, the leukocytes of CGD pa-
tients are unable to produce ROI in response to all the ag-
onists of this enzyme. Fig. 7 shows that the peripheral
blood leukocytes of a CGD patient, lacking p67phox, were
unresponsive to HP-NAP in terms of ROI production.
Finally, we tested the effect of DPI on the HP-NAP
stimulation of neutrophils. DPI is an inhibitor of cellular
flavoproteins (53) and as such inhibits ROI produced by
the NADPH oxidase. Fig. 8 shows that DPI (10 mM)
strongly inhibits HP-NAP–induced ROI production, thus
providing further evidence that this H. pylori virulence fac-
tor acts via activation of the plasma membrane NADPH
oxidase complex.
The Production of ROI Induced by HP-NAP Is Inhibited
by Pertussis Toxin, Wortmannin, and PP1. Activation of
NADPH oxidase in phagocytes is a complex phenomenon
that may or may not depend on the stimulant binding to a
specific receptor. Depending on the chemical nature of the
stimulus, it may implicate G proteins, second messengers,
Figure 5. IFN-g (A) and TNF-a (B) potentiate
the stimulation of ROI production by HP-NAP.
H2O2 was measured with the homovanillic acid
method (reference 34). Before addition of 1.2 mM
HP-NAP, neutrophils were preincubated for 60
min with 5 ng/ml IFN-g or 15 min with 5 ng/ml
TNF-a at 378C. Points are the average of three
different experiments run in triplicate, and bars
represent SD values.
Figure 6. Translocation of cytosolic
components of NADPH oxidase on the
plasma membrane in human neutrophils
stimulated with HP-NAP. Lane 1, un-
stimulated neutrophils; lane 2, neutro-
phils stimulated for 15 min with 3 mM
HP-NAP; lane 3, neutrophils stimulated
with PMA (50 ng/ml) for 15 min. The
conditions of cell stimulation, fraction-
ation, and detection of cells components
are described in Materials and Methods.1472 H. Pylori Neutrophil-activating Protein Is Chemotactic and Immunogenic
activation of protein kinases, and phospholipid turnover
(49, 51). Fig. 8 shows that pertussis toxin and wortmannin
are powerful inhibitors of the HP-NAP–induced ROI
production by neutrophils. Pertussis toxin ADP-ribosylates
the Ga subunits of heterotrimeric G proteins of the Gi and
Go subtypes, which are coupled to heptahelical receptors
and activate phosphatidylinositol-specific phospholipase C
(PtdIns-PLC) (54–56). The present finding is a clear dem-
onstration that one such regulatory GTP-binding protein
mediates the transmission of the HP-NAP signal from the
cell surface to the cell interior. At the same time, it impli-
cates both a heptahelical HP-NAP–specific receptor and a
PtdIns-PLC, which accounts for the generation of the
1,4,5-trisphosphate agonist of the calcium channel present
on the limiting membrane of intracellular calcium stores.
The inhibitory effect of wortmannin is exerted within a
nanomolar range of concentrations at which this drug is
specific for PI3-K and has no toxic effects on human neu-
trophils (57, 58). This is indirect but compelling evidence
that the HP-NAP activation of neutrophils, mediated by a
heterotrimeric G protein, causes a downstream activation
of a PI3-K.
PP1 is a specific inhibitor of a family of Src-selective ty-
rosine kinases (59) that is implicated in NADPH oxidase
activation exerted by some stimulants. Fig. 8 shows that
this is also the case for HP-NAP, indicating that receptor
binding of this stimulant activates a pathway implicating
phosphorylation of tyrosine residues.
HP-NAP Induces an Increase in Cytosolic [Ca21]. The ac-
tivation of NADPH oxidase by receptor-mediated ago-
nists such as C5a, platelet activating factor (PAF), and
FMLP is associated with an increase in cytosolic [Ca21] re-
leased from intracellular stores and influxed from the extra-
cellular medium (60). Fig. 9 shows that HP-NAP induces
an increase of cytosolic calcium concentration in a dose-
dependent manner. When the stimulation was performed
in the absence of external calcium, the [Ca21]i was halved,
indicating an approximately similar contribution of extra-
cellular and intracellular Ca21. The increase in cytosolic
[Ca21] caused by HP-NAP was completely prevented by
pretreatment with pertussis toxin (Fig. 9 C). This result im-
plies that the G protein activated by HP-NAP stimulates a
PLC, which releases 1,4,5-trisphosphate, which in turn
opens intracellular calcium channels, thus leading to the in-
creased cytosolic calcium level documented here. On the
contrary, the effect of HP-NAP on cytosolic [Ca21] was
unaffected by inhibitors of Src tyrosine kinase (PP1) and
phosphatidylinositol 3,4,5-trisphosphate kinase (wortman-
nin) (Fig. 9 C).
In the presence of the intracellular Ca21 chelator
BAPTA (60 mM), HP-NAP was not able to stimulate the
production of ROI (not shown). The effect of BAPTA was
not due to a toxic activity, as cells loaded with this chelator
maintained their responsiveness to PMA (data not shown).
These results indicate that the increase in [Ca21]i plays a
functional role in the sequence of events causing the stimu-
lation of NADPH oxidase by HP-NAP, as it occurs with
chemotactic peptides (60).
Figure 7. HP-NAP does not stimulate H2O2 production in CGD neu-
trophils defective of NADPH oxidase.  Experiments were performed
twice in triplicate, and H2O2 production was measured with the homo-
vanillic acid method (reference 34). Bars represent the SD value.
Figure 8. Effect of DPI (A), pertussis toxin (B), wortmannin (C), and
PP1 (D) on the stimulation of H2O2 production by HP-NAP. Human
neutrophils were preincubated with the indicated inhibitor at the concen-
trations reported in the figure for 5 min at 378C (2 h for pertussis toxin),
before addition of 3 mM HP-NAP, and then assayed as in the legend to
Fig. 5. Data are the average of the results of two different experiments run
in triplicate, and bars represent SD values.1473 Satin et al.
Discussion
The main findings of this work are that HP-NAP pro-
duced by H. pylori: (a) is a major antigen in the human im-
mune response to H. pylori; (b) is capable, after oral immu-
nization, of conferring protection on mice against a
subsequent challenge with H. pylori; (c) is a chemoattrac-
tant for neutrophils and monocytes; and (d) activates the
NADPH oxidase of human leukocytes via a set of signaling
events that are defined here. Moreover, here we provide
quantitative assays of HP-NAP that are essential for evalu-
ating the biological and pathological activity of HP-NAP
derivatives and mutants as well as of HP-NAP–like mole-
cules produced by other bacteria.
Many studies have been devoted to the definition of the
immunogenic properties of H. pylori molecules (16, 26, 27,
38–40). CagA has been considered as an immunodominant
antigen, since anti-CagA antibodies are frequently detected in
sera from individuals infected with CagA1 H. pylori strains
(30, 61, 62), and CD41 T cell clones isolated from the gastric
mucosa of H. pylori–infected subjects are frequently specific
for CagA (63). Antibodies specific for the H. pylori urease,
heat shock proteins, VacA, and other antigens are also found
in sera from H. pylori–infected patients (38–40, 60, 64). Here,
we have shown that H. pylori–infected patients produce anti-
bodies specific for HP-NAP. It is not yet known what role
these antibodies have during the course of H. pylori infection.
However, it is particularly interesting to note that oral admin-
istration of HP-NAP in association with a strong and non-
toxic mucosal adjuvant is capable of protecting mice against a
challenge with H. pylori. Even though the mechanisms of the
inflammatory and immune response to H. pylori infection are
not yet fully understood, we believe that these are major find-
ings with respect to the definition of the virulence factors in-
volved in the pathogenesis of H. pylori–associated diseases and
to the formulation of an anti–H. pylori vaccine.
It was previously shown that HP-NAP promotes neu-
trophil adhesion to endothelial cells and oxygen radical–
mediated reduction of NBT (19, 20). Here we have shown
that HP-NAP is chemotactic for both monocytes and
neutrophils and we have identified the signaling events
involved in their activation. The conclusion that ROI pro-
duction is due to the activation of the classical O2?2
forming NADPH oxidase is supported by three lines of ev-
idence. HP-NAP stimulation of ROI production is associ-
ated with the translocation of the NADPH oxidase cytoso-
lic components p47phox, p67phox, and p40phox to the plasma
membrane of neutrophils, a process that corresponds to the
activation of the oxidase (65). Second, leukocytes of CGD
patients, genetically defective in NADPH oxidase, do not
respond to HP-NAP. Third, DPI, an inhibitor of NADPH
oxidase, prevents the stimulus provided by HP-NAP. After
establishing this point, we attempted to define the intracel-
lular signaling pathways involved in such activation.
It is known that various reactions participate in NADPH
oxidase activation; some of them are always activated re-
gardless of the nature of the stimulant (49–51). Here, we
have shown that the HP-NAP activation of neutrophil
ROI production is consistent with a signaling pathway in-
volving a pertussis toxin–sensitive G protein, an elevation
of cytosolic [Ca21], a Src family of tyrosine kinases sensitive
to PP1, and a wortmannin-sensitive PI3-K. These intracel-
lular signaling events result in an HP-NAP–induced chemo-
tactic response with increased expression of b2 integrin in
both neutrophils and monocytes.
The pattern of events triggered by HP-NAP is closely
similar to that triggered by heptahelical receptors specific
for the chemotactic agonist FMLP, C5a, platelet activating
factor (PAF), and IL-8 (49, 51). Such similarity also
strongly suggests that the HP-NAP receptor is a serpentine
type of cell surface transmembrane protein, but this recep-
tor remains to be identified.
Figure 9. Effect of HP-NAP on [Ca21]i in neutrophils in the absence or presence of pertussis toxin, wortmannin, PP1, and EGTA. (A) Human neu-
trophils loaded with Fura-2 for 25 min were washed and then exposed to the given concentrations of HP-NAP in a stirred fluorimeter cuvette. Fluores-
cence outputs were converted to [Ca21] after calibration. (B) Only part of the increase in cytosolic [Ca21] triggered by HP-NAP (solid line) is due to re-
lease from intracellular stores (broken line). (C) Pertussis toxin completely prevents the HP-NAP–induced rise in cytosolic [Ca21], whereas other
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The fact that HP-NAP is a chemotactic agonist and an acti-
vator of the oxidative metabolism of the inflammatory cells is
relevant for the pathogenic effect of H. pylori at the sites of in-
fection. In fact, HP-NAP can be involved in the extravasation
of leukocytes (gastritis), and ROI, apart from being proinflam-
matory mediators (66, 67), could play a role in the damage of
the stomach mucosa during chronic H. pylori infection. ROI
may also be involved in the generation of mutagenic chemical
species that can contribute to the pathogenesis of H. pylori–
associated stomach cancers (68, 69). HP-NAP has to be con-
sidered an important novel virulence factor of H. pylori–associ-
ated disease whose role in bacterial physiology remains to be
established. Regarding its role in pathogenesis, it is notewor-
thy that there is a correlation between severity of disease and
capability of activating neutrophils of different H. pylori
isolates (19, 20). We also report here that TNF and IFN
potentiate the HP-NAP–induced activation of the NADPH
oxidase. Such priming effects are expected to be relevant to
the in vivo situation, where these proinflammatory cytokines
are likely to potentiate the stimulation of ROI production by
HP-NAP and consequently their pathogenic effect.
The findings presented here make HP-NAP a strong candi-
date for a multicomponent H. pylori vaccine. However, on the
basis of the results obtained with human leukocytes, it should
be clarified whether HP-NAP needs to be modified in such a
way as to lose its phagocyte-stimulating activity while preserv-
ing its immunogenicity, or whether the stimulatory properties
are prerequisites for optimal stimulation of the immune re-
sponse. The region(s) of HP-NAP involved in the interaction
with cell surface receptor(s) remain(s) to be identified; such
information may be acquired via generation of site-directed
mutants, designed from recent structural data (25), which are
underway. The present definition of quantitative assays of its
biological activities and the information on the cellular signal-
ing pathways activated by HP-NAP are prerequisites for the
careful evaluation of the properties of such HP-NAP mutants.
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